L
Li-an Xu
Researcher at Bristol-Myers Squibb
Publications - 13
Citations - 4707
Li-an Xu is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Gene & Medicine. The author has an hindex of 4, co-authored 4 publications receiving 3868 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
The reference genome of Camellia chekiangoleosa provides insights into Camellia evolution and tea oil biosynthesis
Tengfei Shen,Bin Huang,Meng-Shu Xu,Peng Zhou,Zhouxian Ni,Chun Gong,Qiang Wen,Fuliang Cao,Li-an Xu +8 more
TL;DR: The first chromosome-level genome of oil-tea trees will provide valuable resources for determining Camellia evolution and utilizing the germplasm of this taxon.
Journal ArticleDOI
CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Li-an Xu,Ian M. Waxman,Padmanee Sharma,CheckMate Investigators +21 more
Journal ArticleDOI
Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).
Elizabeth R. Plimack,Hans J. Hammers,Brian I. Rini,David F. McDermott,Bruce G. Redman,Timothy M. Kuzel,Michael R. Harrison,Ulka N. Vaishampayan,Harry A. Drabkin,Saby George,Theodore F. Logan,Kim Margolin,Li-an Xu,Ian M. Waxman,Robert J. Motzer +14 more
TL;DR: NIVO, a programmed death-1 immune checkpoint inhibitor, demonstrated encouraging clinical activity in a randomized phase II study in pts with mRCC pretreated with targeted VEGF pat...
Journal ArticleDOI
Genome-Wide Identification of PLATZ Transcription Factors in Ginkgo biloba L. and Their Expression Characteristics During Seed Development
TL;DR: This study provides a basis for understanding the structural differentiation, evolutionary characteristics, expression profile, and potential functions of PLATZ transcription factors in Ginkgo biloba.